Table 1.
Characteristics of 35 HER2 negative mBC patients treated with Bevacizumab plus Paclitaxel followed by maintenance Bevacizumab
| Total number of patients (n = 35) | Frequency (%) |
|---|---|
| Median age (range) |
50 (32–72) |
| Menopausal Status |
|
| Pre |
6 (17.1) |
| Post |
29 (82.9) |
| Hormonal Receptor Status |
|
| Negative |
5 (14.3) |
| Positive |
30 (85.7) |
| Triple negative |
5 (14.3) |
| Adjuvant chemotherapy |
|
| - None |
13 (37.1) |
| - including anthracyclines |
9 (25.7) |
| - including antracyclines + taxanes |
9 (25.7) |
| - Other regimens |
4 (11.4) |
| Adjuvant hormonal therapy |
22 (62.8) |
| Visceral metastatic sites |
23 (65.7) |
| Median Disease Free Survival, months (range) |
30 (0–362) |
| Median Cycles of Bevacizumab + Paclitaxel (range) |
8 (6–12) |
| Median cycles of three-weekly mBev (range) |
7 (1 – 28) |
| Median PS at the start of mBev (range) | 0 (0–1) |
PS, Performance Status (ECOG); Triple negative, estrogen receptor, progesteron receptor, HER2 negative; mBev, mainteinance Bevacizumab.